Shandong Haiya Pharmaceutical Technology

Shandong Haiya Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Jinan, China, dedicated to the development of innovative small molecule drugs for metabolic and inflammatory conditions. The company's flagship candidate, HY-0902, is a novel Urate Transporter 1 (URAT1) inhibitor currently undergoing Phase 2 clinical trials for the treatment of gout and hyperuricemia. Developed through a strategic partnership with the School of Pharmaceutical Sciences at Shandong University, HY-0902 aims to provide a safer and more effective alternative to current standard-of-care therapies. Beyond its lead program, Haiya is advancing a pipeline of early-stage candidates, including HY-1012 and HY-1013, and is investing in an AI-driven siRNA drug discovery platform. The company combines academic research excellence with industrial development capabilities to address significant unmet medical needs.